<DOC>
	<DOCNO>NCT00003894</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may interfere body 's ability recognize transplant bone marrow cell foreign may help treat patient graft-versus-host disease . PURPOSE : Randomized phase II trial study effectiveness thalidomide treat patient chronic graft-versus-host disease follow bone marrow transplantation .</brief_summary>
	<brief_title>Thalidomide Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy thalidomide patient steroid dependent refractory chronic graft v host disease follow allogeneic bone marrow transplant . II . Determine toxicity regimen patient . OUTLINE : This randomize study . Patients stratify accord type bone marrow transplant receive ( allogeneic v match unrelated donor ) type chronic graft v host disease ( steroid dependent v steroid refractory ) . Patients receive either oral thalidomide placebo 2-4 time day 6 month . The drug taper stop . If disease recurs , drug may restart second 6 month course . The maximum duration treatment 18 month . Patients continue steroid therapy , taper study therapy . If response see 8 week , patient may cross alternate drug . Patients follow weekly 1 month , every month 1 year . PROJECTED ACCRUAL : A total 36 patient ( 18 per arm ) accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm chronic graft v host disease follow allogeneic bone marrow transplant ( BMT ) Greater 100 day since BMT Must receive least 1 mg/kg prednisone equivalent immunosuppression PATIENT CHARACTERISTICS : Age : 3 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : Not specify Endocrine therapy : See Disease Characteristics Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>graft versus host disease</keyword>
</DOC>